

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONEE FOR PATENTS
P. D. Stat 1450
Alexandria, Viginia 22113-1450

www.unplo.gov

Bib Data Sheet

CONFIRMATION NO. 8149

CONTINUING DATA This application is a DIV of 09/706,540 11/04/2000 PAT 6,689,753 which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS TOPL FOREIGN APPLICATIONS TOPL FOREIGN FILING LICENSE GRANTED 03/15/2004 Treign Priority claimed were with the priority claimed with abnormal origin folding into amyloid, amyloid like deposits or beta sheet rich pathological precursor thereof TILE USE OF A Sheet Breaker Perhide Phalogs Heat Inhibit A pleated Sheet formation in amyloid and properly and provided and provided and the provided	DID DOIG GITCCI				• •			
CONTINUING DATA This application is a DIV of 09/706,540 11/04/2000 PAT 6,689,753 which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS NOING REQUIRED, FOREIGN FILING LICENSE GRANTED 03/15/2004 reign Priority claimed		DATE 12/03/2003	1	GR		ם ייי	OCKET NO.	
This application is a DIV of 09/706,540 11/04/2000 PAT 6,689,753 which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS Which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS Which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS Which claims benefit of 60/163,911 11/05/1999 Which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS Which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS Which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS Which claims benefit of 60/163,911 11/05/1999 TOTAL CLAIMS CLAIMS CLAIMS 6 STATE OR COUNTRY SWITZERLAND SHEETS COUNTRY SWITZERLAND FOREIGN APPLICATIONS TOTAL CLAIMS CLAIMS 6 CLAIMS 6 FOREIGN APPLICATIONS TOTAL CLAIMS CLAIMS 6 FOREIGN APPLICATIONS TOTAL CLAIMS 6 CLAIMS 6 TOTAL CLAIMS 6 CLAIMS 6 TOTAL CLAIM	APPLICANTS							
This application is a DIV of 09/706,540 11/04/2000 PAT 6,689,753 which claims benefit of 60/163,911 11/05/1999 FOREIGN APPLICATIONS ***Notify Decimal Priority claimed	Claudio So	to-Jara, Genėva, SWITZER	RLAND;					
REQUIRED, FOREIGN FILING LICENSE GRANTED 03/15/2004 reign Priority claimed	This applica	ation is a DIV of 09/706.540	** 0 11/04/2000 PAT 6 /05/1999 · · · · · · · · ·	6,689,753	-ВВВ "\	a105		
103/15/2004 reign Priority claimed	** FOREIGN APP	LICATIONS ************************************	 il BOB 11/9/	D5		•		
USC 119 (a-d) conditions	IF REQUIRED, FO ** 03/15/2004	OREIGN FILING LICENSE	GRANTED					
TILE USE OF B sheet Breaker Perhide Handogs that Inhibit B pleated Sheet formation in amylvid perhide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal otein folding into amyloid, amyloid like deposits or beta sheet rich pathological precursor thereof FILING FEE RECEIVED 1478 FEES: Authority has been given in Paper RECEIVED 100 to charge/credit DEPOSIT ACCOUNT No for following: 1.18 Fees (Issue) Other	Foreign Priority claime	ed 🔲 yes 🖾 no						
TLE USE OF β sheet Breaker Peptide Analogs that Inhibit β pleated sheet formation in amylvid β eptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal otein folding into amyloid, amyloid like deposits or beta sheet rich pathological precursor thereof FILING FEE RECEIVED 1478 FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following: 1.18 Fees (Issue) Other		Budget E. Dunner	fer COUNT SWITZER	RY DF	RAWING	CLAIMS	CLAIMS	
TLE USE OF B sheet Breaker Peptide Whalogs that Inhibit B pleated Sheet formation in amylvid peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal otein folding into amyloid like deposits or beta sheet rich pathological precursor thereof FILING FEE FEES: Authority has been given in Paper RECEIVED No to charge/credit DEPOSIT ACCOUNT No for following: TLE USE OF B sheet Breaker Peptide Whalogs that Inhibit B pleated Sheet formation in amylvid peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in the treatment of diseases associated with abnormal otein following in t	ADDRESS 24247		···		,			
FILING FEE RECEIVED 1478 FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following: All Fees		B sheet Breaker Peptid	e Analogs that I	Chhibit R	pleated She	et formati	ion in amyloid B	
FILING FEE RECEIVED 1478 FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following: 1.16 Fees (Filing) 1.17 Fees (Processing Ext. of time) 1.18 Fees (Issue) Other	Reptide analogs a protein folding into	and mimetics suitable for in a amyloid, amyloid like dep	vivo use in the trea	itment of c	diseases asso liogical precu	ociated with rsor thereto	h abnormal	
FILING FEE RECEIVED 1478 FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following: 1.16 Fees (Filing) 1.17 Fees (Processing Ext. of time) 1.18 Fees (Issue) Other			· · · · · · · · · · · · · · · · · · ·					
No to charge/credit DEPOSIT ACCOUNT time time 1478 No for following: time 1.18 Fees (Issue) Other		•						
Other	FILING FEE	FEES: Authority has been g	COUNT					
	1478	No for following:						
☐ Credit						Other		
						☐ Credit		

19105